Vulnerability of esophageal cancer to their addiction to kinase activities

Portrait de Xavier Bisteau Xavier Bisteau
Faculty of Médecine

In decades, the survival rate of patients with esophageal squamous cell carcinoma (eSCC) has barely improved, making this cancer one of the deadliest. Those tumors are highly heterogenous and harbor a variety of gene alterations, impairing the development of a unique therapeutic strategy. Nevertheless, the CDK4 kinase has appeared to be one of the current privileged target as its activity integrates the majority of the oncogenic aberrations to push the oncogenic proliferation.

For his “Kinaddict” project, Xavier Bisteau will evaluate the response of eSCC tumors to kinase inhibitors and decipher their associate molecular response. Within Pierre Roger’s team (IRIBHM), he will identify the kinases with a deregulated activity of which tumors are addicted. By combining kinase inhibitors, this will allow to define new efficient treatment modalities on those tumors using in vitro and in vivo murine models, leading to alternative therapies for patients.

End of the project: 15-09-2021

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 843107
Created on February 11, 2020